New Delhi News

DelveInsight’s “Knee Osteoarthritis Pipeline Insight 2026” report provides comprehensive insights about 55+ companies and 65+ pipeline drugs in the Knee Osteoarthritis pipeline landscape. It covers the Knee Osteoarthritis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Knee Osteoarthritis Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Knee Osteoarthritis Pipeline? @ https://www.delveinsight.com/sample-request/knee-osteoarthritis-pipeline-insight

Key Takeaways from the Knee Osteoarthritis Pipeline Report

• In May 2026- Amzell initiated a 6-week trial of a formulation of AMZ001 once daily versus placebo once daily. Participants will be evaluated for osteoarthritis by X-ray images of the knees and one knee will be selected for treatment as the target knee. The study gel will be applied directly to that knee throughout the 6 weeks of the study.
• In May 2026- Kolon TissueGene Inc. conducted a phase 3 study to determine the efficacy and safety of TG-C in subjects with Kellgren and Lawrence Grade 2 or 3 Osteoarthritis of the Knee, Osteoarthritis Research Society International (OARSI) medial joint space narrowing (JSN) Grade 1 or 2 of the knee joint. TG-C is to be administered by a single intra-articular injection to the damaged joint area via ultrasound guidance. Patients will be followed for 24 months for safety and efficacy.
• In May 2026- Paradigm Biopharmaceuticals Ltd. announced a phase 3 study is to measure the change in pain and function with subcutaneous injections of pentosan polysulfate sodium (PPS) compared with subcutaneous injections of placebo in participants with knee OA pain.
• DelveInsight’s Knee Osteoarthritis Pipeline report depicts a robust space with 55+ active players working to develop 65+ pipeline therapies for Knee Osteoarthritis treatment.
• The leading Knee Osteoarthritis Companies such as Saol Therapeutics Inc, 4P-Pharma, Nuwacell Biotechnologies Co., Ltd., Belief BioMed (Beijing) Co., Ltd, Sanofi, Pacira Pharmaceuticals, Inc, Genascence Corporation, Anterogen Co., Ltd., Avidence Therapeutics, Cytonics Corporation, CarthroniX, Inc., Calliditas Therapeutics, ICM Co. Ltd., Addpharma Inc., Peptinov SAS, Novartis, Ageless Biotech, Inc., OrthoTrophix, Inc, Nordic Bioscience, Amzell, CellSeed Inc., Doron Therapeutics Inc., Novo Nordisk A/S, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Beijing Aosaikang Pharmaceutical Co., Ltd. and others.
• Promising Knee Osteoarthritis Therapies such as Civamide, SYN321, Clodronate, LBSA0103, Pelubiprofen CR 45mg tab., Tirzepatide, CLS2901C, RN624 (PF-04383119), Allocetra, RHH646, TLC599 and others.

Want to know which companies are leading innovation in Knee Osteoarthritis? @ Knee Osteoarthritis Clinical Trials Assessment

The Knee Osteoarthritis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Knee Osteoarthritis Pipeline Report also highlights the unmet needs with respect to the Knee Osteoarthritis.

Knee Osteoarthritis Overview

Knee osteoarthritis (OA), also known as degenerative joint disease, is typically the result of wear and tear and progressive loss of articular cartilage. It is most common in the elderly. Knee osteoarthritis can be divided into two types, primary and secondary. Primary osteoarthritis is articular degeneration without any apparent underlying reason. Secondary osteoarthritis is the consequence of either an abnormal concentration of force across the joint as with post-traumatic causes or abnormal articular cartilage, such as rheumatoid arthritis (RA). Osteoarthritis is typically a progressive disease that may eventually lead to disability. The intensity of the clinical symptoms may vary for each individual. However, they typically become more severe, more frequent, and more debilitating over time. The rate of progression also varies for each individual. Common clinical symptoms include knee pain that is gradual in onset and worse with activity, knee stiffness and swelling, pain after prolonged sitting or resting, and pain that worsens over time.

Knee Osteoarthritis Emerging Drugs Profile

• SL-1002: Saol Therapeutics Inc.

SL-1002 is a novel, chemoneurolytic injection, that utilizes Saol’s proprietary CYCLOPHLEXTM technology. It is a proprietary chemoneurolytic agent designed to destroy nerve tissue to block pain or spasticity signals. It is currently being developed for the treatment of chronic knee pain related to osteoarthritis and limb spasticity, both in the adult population in the United States. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Knee Osteoarthritis.

• 4P004: 4P-Pharma

4P004 is a pioneering, first-in-class Disease-Modifying Osteoarthritis Drug (DMOAD) developed by 4Moving Biotech as a GLP-1 analog for knee osteoarthritis. It is designed to be injected intra-articularly to reduce inflammation and structural damage. It has FDA Fast Track Designation and is currently in Phase IIa trials, with top-line results expected in early 2027. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Knee Osteoarthritis.

• NCR100: Nuwacell Biotechnologies Co., Ltd.

NCR100 is an investigational cell therapy developed by Nuwacell Biotech Co., Ltd., based on induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (iMSCs). It is designed primarily for the treatment of knee osteoarthritis and represents the first iPSC-derived mesenchymal stem cell product approved for clinical trials in China. Mechanistically, NCR100 leverages the regenerative and immunomodulatory properties of mesenchymal stem cells, including tissue repair, anti-inflammatory effects, promotion of angiogenesis, and support of endogenous cell regeneration. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Knee Osteoarthritis.

• BBM-A101: Belief BioMed (Beijing) Co., Ltd

BBM-A101 is an investigational, bio-engineered adeno-associated virus (AAV) vector gene therapy developed by Belief BioMed to treat knee osteoarthritis (KOA). Administered via intra-articular injection, it delivers a human anti-inflammatory protein gene to reduce pain and inflammation while potentially slowing disease progression. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Knee Osteoarthritis.

If you’re tracking ongoing Knee Osteoarthritis Clinical trials @ Knee Osteoarthritis Treatment Drugs

The Knee Osteoarthritis Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of Knee Osteoarthritis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Knee Osteoarthritis Treatment.
• Knee Osteoarthritis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Knee Osteoarthritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Knee Osteoarthritis market.

Knee Osteoarthritis Companies

Saol Therapeutics Inc, 4P-Pharma, Nuwacell Biotechnologies Co., Ltd., Belief BioMed (Beijing) Co., Ltd, Sanofi, Pacira Pharmaceuticals, Inc, Genascence Corporation, Anterogen Co., Ltd., Avidence Therapeutics, Cytonics Corporation, CarthroniX, Inc., Calliditas Therapeutics, ICM Co. Ltd., Addpharma Inc., Peptinov SAS, Novartis, Ageless Biotech, Inc., OrthoTrophix, Inc, Nordic Bioscience, Amzell, CellSeed Inc., Doron Therapeutics Inc., Novo Nordisk A/S, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Beijing Aosaikang Pharmaceutical Co., Ltd. and others.

Knee Osteoarthritis Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Knee Osteoarthritis Products have been categorized under various Molecule types such as,

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

From emerging drug candidates to competitive intelligence, the Knee Osteoarthritis Pipeline Report @ Knee Osteoarthritis Market Drivers and Barriers, and Future Perspectives

Scope of the Knee Osteoarthritis Pipeline Report

• Coverage- Global
• Knee Osteoarthritis Companies- Saol Therapeutics Inc, 4P-Pharma, Nuwacell Biotechnologies Co., Ltd., Belief BioMed (Beijing) Co., Ltd, Sanofi, Pacira Pharmaceuticals, Inc, Genascence Corporation, Anterogen Co., Ltd., Avidence Therapeutics, Cytonics Corporation, CarthroniX, Inc., Calliditas Therapeutics, ICM Co. Ltd., Addpharma Inc., Peptinov SAS, Novartis, Ageless Biotech, Inc., OrthoTrophix, Inc, Nordic Bioscience, Amzell, CellSeed Inc., Doron Therapeutics Inc., Novo Nordisk A/S, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Beijing Aosaikang Pharmaceutical Co., Ltd. and others.
• Knee Osteoarthritis Therapies- Civamide, SYN321, Clodronate, LBSA0103, Pelubiprofen CR 45mg tab., Tirzepatide, CLS2901C, RN624 (PF-04383119), Allocetra, RHH646, TLC599 and others.
• Knee Osteoarthritis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Knee Osteoarthritis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the Knee Osteoarthritis Treatment landscape in this detailed analysis @ Knee Osteoarthritis Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Knee Osteoarthritis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Knee Osteoarthritis – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. SL-1002: Saol Therapeutics Inc.
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. 4P004: 4P-Pharma
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. BBM-A101: Belief BioMed (Beijing) Co., Ltd
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Knee Osteoarthritis Key Companies
21. Knee Osteoarthritis Key Products
22. Knee Osteoarthritis Unmet Needs
23. Knee Osteoarthritis Market Drivers and Barriers
24. Knee Osteoarthritis Future Perspectives and Conclusion
25. Knee Osteoarthritis Analyst Views
26. Knee Osteoarthritis Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/knee-osteoarthritis-pipeline-insight